This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Is Zimmer Biomet (ZBH) a Great Stock for Value Investors?
by Zacks Equity Research
Is Zimmer Biomet (ZBH) a great pick from the value investor's perspective right now? Read on to know more.
Zimmer Biomet (ZBH) Launches Persona Partial Knee System
by Zacks Equity Research
Zimmer Biomet (ZBH) is constantly trying to turn its Knees business around. Keeping in line with the efforts, the company has launched Persona Partial Knee System.
New Strong Sell Stocks for September 6th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zimmer (ZBH) Plagued by Various Internal and External Issues
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to suffer a bad patch, entangled with issues including its decade-old CEO's recent exit post a dull earnings season due to poor knee business.
New Strong Sell Stocks for August 14th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Zimmer (ZBH) Tops Q2 Earnings, Drops View on Dull Sales
by Zacks Equity Research
Zimmer Biomet's (ZBH) Q2 earnings results disappoint with an unimpressive Knee, Hip and Dental performances.
Zimmer Biomet (ZBH) Misses Q2 Earnings, Meets Sales Estimate
by Zacks Equity Research
Zimmer Biomet's (ZBH) Knees and Hips segment decreases year over year.
Zimmer Biomet's Preliminary Q2 Numbers Solid, CEO Steps Down
by Zacks Equity Research
Indiana-based Zimmer Biomet Holdings, Inc. (ZBH), a leading player in the global musculoskeletal space, recently announced second-quarter 2017 preliminary results.
Zimmer Biomet (ZBH) Launches X-Ray-Based X-PSI Knee System
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) recently launched a X-ray-based Patient Specific Instrument, X-PSI Knee System.
FDA Passes Zimmer Biomet's (ZBH) Zhejiang Facility Issue
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) revealed that the U.S. Food and Drug Administration (FDA) has closed out its 'Warning Letter' related to the company's Zhejiang, China manufacturing facility.
Zimmer Biomet Rides on Spine Business, Knee Challenges Stay
by Zacks Equity Research
On Jun 6, we issued an updated research report on Warsaw, IN-based Zimmer Biomet Holdings Inc. (ZBH).
Zimmer Biomet (ZBH) Beats on Q1 Earnings and Sales Estimates
by Zacks Equity Research
Zimmer Biomet has a Zacks Rank #3 (Hold) but that could change following its first quarter 2017 earnings report which has just released.
Should You Buy Zimmer Biomet (ZBH) Ahead of Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Medical Product Stocks' Earnings on Apr 27: ZBH, RMD & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their Jan-Mar 2017 quarter's reports on Apr 27.
Will Zimmer Biomet (ZBH) Beat Earnings Estimates in Q1?
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) is expected to beat earnings when it reports its first-quarter 2017 financial numbers on Apr 27.
Is Zimmer Biomet (ZBH) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Zimmer Biomet Holdings, Inc. (ZBH) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
MedTech Long-Term Prospects Impress: Which Stocks to Buy?
by Zacks Equity Research
President Trump will finally replace the ACA and implement his own strategy, the nation is clearly divided into "we need" and "don't need" camps.
Zimmer Biomet (ZBH): Tops Q4 Earnings Estimates, Meets Sales
by Zacks Equity Research
Zimmer Biomet (ZBH) has posted mixed results with its earnings surpassing the Zacks Consensus Estimate and revenues in line with the mark.
Medical Products Stocks' Earnings on Jan 31: ZBH, TMO, ABC
by Zacks Equity Research
Let's take a look at the major Medical Product stocks slated to release their earnings results on tomorrow.
Zimmer Biomet (ZBH) Q4 Earnings: A Surprise in the Cards?
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) is expected to report fourth-quarter 2017 financial numbers on Jan 31, before the opening bell.
Does Zimmer Biomet Make for a Suitable Value Investment?
by Zacks Equity Research
The solid Key Value Statistics are likely to make Zimmer Biomet (ZBH) a decent pick for the value investors.
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Nxstage Medical
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Medtronic, Zimmer Biomet and Roche
MedTech Sails Through Macro Woes: Stocks in Focus
by Zacks Equity Research
Mergers & acquisitions, emerging market expansion, positive demographic trends and new product innovation are the vital forces behind the continued uptrend in the sector's performance.
MedTech Industry Stock Outlook - December 2016
by Zacks Equity Research
The Republican win marked a great victory for the entire medical device industry as the likelihood of a permanent repeal of the 2.3% medical device excise tax will come as a big bonus.